Our particular drug is the most potent of all those that are out there. And as a result of that it could be administered in a very small volume and we anticipate that will be less than 1 ml of fluid given once per month subcutaneously. It’s also quite stable which will allow us to ultimately have this available for self-administration. As far as I know it’s the only one that’s out there. And we have seen virtually no injection side reactions, which again, if you look at the label of the competitors, in no case are they devoid of injection side reactions. So that’s potentially another advantage.So I think from it’s both physical and [chemical] characteristics and its potency and its ease of use, plus its mechanism, it’s clearly distinct from the other candidates or the drugs that are out there.
XOMA's Management Presents At Morgan Stanley Global Healthcare Conference (Transcript)
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.